PRKD3 promotes malignant progression of OSCC by downregulating KLF16 expression.

CONCLUSIONS: The highly-expressed PRKD3, remarkably associated with metastasis incidence and poor prognosis of OSCC patients, may accelerate the malignant progression of OSCC through modulating KLF16 expression. PMID: 33378018 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/33378018?dopt=Abstract

Source: European Review for Medical and Pharmacological Sciences - January 1, 2021 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research